International Urology and Nephrology

, Volume 50, Issue 4, pp 611–617 | Cite as

Effects of metformin on prostatic tissue of rats with metabolic syndrome and benign prostatic hyperplasia

  • Congyun Xu
  • Yan Xu
  • Zhou Shen
  • Hangcheng Zhou
  • Jun Xiao
  • Tao Huang
Urology - Original Paper



To investigate the efficacy of insulin sensitizer on prostatic tissue in animal model with benign prostatic hyperplasia (BPH) secondary to metabolic syndrome (MetS).


Models were established by providing Sprague–Dawley rats with high fat diet (HFD) combined with metformin or not. All objects were killed 40 days later with prostatic tissue being removed, weighed before stained, as well as the expression level of insulin-like growth factor I (IGF-1) and receptor (IGF-1R) being measured, and the level of insulin resistance (IR) has also been evaluated.


Model has been successfully established. Level of prostatic hyperplasia and IR as well as IGF-1 and IGF-1R expressions in the blank and saline control subunits of HFD group was higher than that of normal diet group (P < 0.05). In the subunit of metformin, along with the suppression of IR, the level of prostatic hyperplasia and the expression of IGF-1 pathway have both decreased (P < 0.05).


MetS can promote the growth of prostate during the formation of central obesity and IR. IGF-1 pathway may have an important role in the induction of BPH following IR. The application of metformin can suppress the expression of IGF-1 and IGF-1R, thus preventing the promotive effect of IR on prostate tissue in animal model of MetS.


Benign prostatic hyperplasia Metabolic syndrome Insulin-like growth factor I Receptor, IGF type 1 Insulin resistance Metformin 



Relevant personnel from the department of pathology, laboratory animal center, and urology of Anhui provincial hospital have provided a great deal of help.


This study was funded by Natural Science Foundation of Anhui Province (1408085QH152).

Compliance with ethical standards

Conflict of interest

All the authors declare that they have no conflict of interest.

Ethics committee

The use of animal in this research was approved by the ethics committee of experimental animal of Anhui medical university.


  1. 1.
    Parsons JK (2010) Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. Curr Bladder Dysfunct Rep 5(4):212–218CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Kasturi S, Russell S, McVary KT (2006) Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr Urol Rep 7(4):288–292CrossRefPubMedGoogle Scholar
  3. 3.
    Vignozzi L, Gacci M, Maggi M (2016) Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat Rev Urol 13(2):108–119CrossRefPubMedGoogle Scholar
  4. 4.
    Antunes LC, Elkfury JL, Jornada MN, Foletto KC, Bertoluci MC (2016) Validation of HOMA-IR in a model of insulin-resistance induced by a high-fat diet in Wistar rats. Arch Endocrinol Metab 60(2):138–142CrossRefPubMedGoogle Scholar
  5. 5.
    Gacci M, Corona G, Vignozzi L, Salvi M, Serni S, De Nunzio C, Tubaro A, Oelke M, Carini M, Maggi M (2015) Metabolic syndrome and benign prostatic enlargement: a systematic review and meta- analysis. BJU Int 115(1):24–31CrossRefPubMedGoogle Scholar
  6. 6.
    Gacci M, Sebastianelli A, Salvi M, De Nunzio C, Tubaro A, Vignozzi L, Corona G, McVary KT, Kaplan SA, Maggi M, Carini M, Serni S (2015) Central obesity is predictive of persistent storage LUTS after surgery for benign prostatic enlargement: results of a multicenter prospective study. BJU Int 116(2):271–277CrossRefPubMedGoogle Scholar
  7. 7.
    Lee RK, Chung D, Chughtai B, Te AE, Kaplan SA (2012) Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms. BJU Int 110(4):540–545CrossRefPubMedGoogle Scholar
  8. 8.
    Russo GI, Castelli T, Privitera S, Fragalà E, Favilla V, Reale G, Urzì D, La Vignera S, Condorelli RA, Calogero AE, Cimino S, Morgia G (2015) Increase of Framingham cardiovascular disease risk score is associated with severity of lower urinary tract symptoms. BJU Int 116(5):791–796CrossRefPubMedGoogle Scholar
  9. 9.
    De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK (2012) The correlation between metabolic syndrome and prostatic diseases. Eur Urol 61(3):560–570CrossRefPubMedGoogle Scholar
  10. 10.
    Minutoli L, Altavilla D, Marini H, Rinaldi M, Irrera N, Pizzino G, Bitto A, Arena S, Cimino S, Squadrito F, Russo GI, Morgia G (2014) Inhibitors of apoptosis proteins in experimental benign prostatic hyperplasia: effects of serenoa repens, selenium and lycopene. J Biomed Sci 21:19CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Kassi E, Pervanidou P, Kaltsas G, Chrousos G (2011) Metabolic syndrome: definitions and controversies. BMC Med 9:48CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Zou C, Gong D, Fang N, Fan Y (2016) Meta-analysis of metabolic syndrome and benign prostatic hyperplasia in Chinese patients. World J Urol 34(2):281–289CrossRefPubMedGoogle Scholar
  13. 13.
    De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schröder F, Sciarra A, Tubaro A (2011) The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 60(1):106–117CrossRefPubMedGoogle Scholar
  14. 14.
    Wang Z, Olumi AF (2011) Diabetes, growth hormone-insulin-like growth factor pathways and association to benign prostatic hyperplasia. Differentiation 82(4–5):261–271CrossRefPubMedGoogle Scholar
  15. 15.
    Gacci M, Vignozzi L, Sebastianelli A, Salvi M, Giannessi C, De Nunzio C, Tubaro A, Corona G, Rastrelli G, Santi R, Nesi G, Serni S, Carini M, Maggi M (2013) Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. Prostate Cancer Prostatic Dis 16(1):101–116CrossRefPubMedGoogle Scholar
  16. 16.
    Neuhouser ML, Schenk J, Song YJ, Tangen CM, Goodman PJ, Pollak M, Penson DF, Thompson IM, Kristal AR (2008) Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. Prostate 68(13):1477–1486CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Rohrmann S, Giovannucci E, Smit E, Platz EA (2007) Association of IGF-1 and IGFBP-3 with lower urinary tract symptoms in the third national health and nutrition examination survey. Prostate 67(15):1693–1698CrossRefPubMedGoogle Scholar
  18. 18.
    Luo J, Dunn T, Ewing C, Sauvageot J, Chen Y, Trent J, Isaacs W (2002) Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis. Prostate 51(3):189–200CrossRefPubMedGoogle Scholar
  19. 19.
    Fiorelli G, De Bellis A, Longo A, Giannini S, Natali A, Costantini A, Vannelli GB, Serio M (1991) Insulin-like growth factor-I receptors in human hyperplastic prostate tissue: characterization, tissue localization, and their modulation by chronic treatment with a gonadotropin-releasing hormone analog. J Clin Endocrinol Metab 72(4):740–746CrossRefPubMedGoogle Scholar
  20. 20.
    Monti S, Di Silverio F, Iraci R, Martini C, Lanzara S, Falasca P, Poggi M, Stigliano A, Sciarra F, Toscano V (2001) Regional ariations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens. J Clin Endocrinol Metab 86(4):1700–1706PubMedGoogle Scholar
  21. 21.
    Li W, Wu CL, Febbo PG, Olumi AF (2007) Stromally expressed c-Jun regulates proliferation of prostate epithelial cells. Am J Pathol 171(4):1189–1198CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Ruan W, Powell-Braxton L, Kopchick JJ, Kleinberg DL (1999) Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development. Endocrinology 140(5):1984–1989CrossRefPubMedGoogle Scholar
  23. 23.
    Kaplan SA, Lee JY, O’Neill EA, Meehan AG, Kusek JW (2013) Prevalence of low testosterone and its relationship to body mass index in older men with lower urinary tract symptoms associated with benign prostatic hyperplasia. Aging Male 16(4):169–172CrossRefPubMedGoogle Scholar
  24. 24.
    Kahn BB, Alquier T, Carling D, Hardie DG (2005) AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1:15–25CrossRefPubMedGoogle Scholar
  25. 25.
    Colquhoun AJ et al (2012) Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer. Prostate Cancer Prostatic Dis 15:346–352CrossRefPubMedGoogle Scholar
  26. 26.
    Ruiter R et al (2012) Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care 35(1):119–124CrossRefPubMedGoogle Scholar
  27. 27.
    Murtola TJ et al (2008) Antidiabetic medication and prostate cancer risk: a population-based case-control study. Am J Epidemiol 168(8):925–931CrossRefPubMedGoogle Scholar
  28. 28.
    He XX, Tu SM, Lee MH et al (2011) Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol 22(12):2640–2645CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Margel D et al (2013) Metformin use and all-cause and prostate cancer- specific mortality among men with diabetes. J Clin Oncol 31(25):3069–3075CrossRefPubMedGoogle Scholar
  30. 30.
    Wright JL, Stanford JL (2009) Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 20(9):1617–1622CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Kusturica J, Kulo Ćesić A, Gušić E, Maleškić S, Rakanović-Todić M, Šečić D (2017) Metformin use associated with lower risk of cancer in patients with diabetes mellitus type 2. Med Glas (Zenica) 14(2):176–181Google Scholar
  32. 32.
    Zhang Y, Li MX, Wang H, Zeng Z, Li XM (2015) Metformin down-regulates endometrial carcinoma cell secretion of IGF-1 and expression of IGF-1R. Asian Pac J Cancer Prev 16(1):221–225CrossRefPubMedGoogle Scholar
  33. 33.
    Wang Z, Xiao X, Ge R, Li J, Johnson CW, Rassoulian C, Olumi AF (2017) Metformin inhibits the proliferation of benign prostatic epithelial cells. PLoS ONE 12(3):e0173335CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Mosli HH, Esmat A, Atawia RT, Shoieb SM, Mosli HA, Abdel-Naim AB (2015) Metformin attenuates testosterone-induced prostatic hyperplasia in rats: a pharmacological perspective. Sci Rep 23(5):15639CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V., part of Springer Nature 2018

Authors and Affiliations

  • Congyun Xu
    • 1
  • Yan Xu
    • 1
  • Zhou Shen
    • 1
  • Hangcheng Zhou
    • 2
  • Jun Xiao
    • 1
  • Tao Huang
    • 1
  1. 1.Department of Urology, Anhui Provincial HospitalThe First Affiliated Hospital of University of Science and Technology of ChinaHefeiChina
  2. 2.Department of Pathology, Anhui Provincial HospitalThe First Affiliated Hospital of University of Science and Technology of ChinaHefeiChina

Personalised recommendations